SCHEMBL6133469

SCHEMBL6133469

CCOC(=O)c1nc(-c2ccccc2)c(-c2ccc(=O)n(CCOC)n2)s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.47
HSD17B10 Q99714 3/20 0.46
CYP1A2 P05177 1/20 0.46
PTGS2 P35354 1/20 0.42
POLB P06746 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
PDE4A P27815 2/20 0.41
PDE4B Q07343 2/20 0.41
PDE4C Q08493 2/20 0.41
PDE4D Q08499 2/20 0.41
PDE3B Q13370 1/20 0.41
PDE3A Q14432 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TP53 P04637 2/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
HPGD P15428 1/20 0.40
RARA P10276 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6133474 0.91 HTT (0.50) HTTHSD17B10CYP1A2PTGS2POLB
SCHEMBL6133966 0.89 HTT (0.52) HTTHSD17B10CYP1A2PTGS2POLB
SCHEMBL6133402 0.87 KDM4E (0.41) HTTHSD17B10CYP1A2POLBPDE4A
SCHEMBL6133344 0.87 SMN1; SMN2 (0.55) HTTHSD17B10CYP1A2PTGS2POLB
SCHEMBL6134322 0.86 PTGS2 (0.46) HTTHSD17B10CYP1A2PTGS2SMN1; SMN2
SCHEMBL6134080 0.86 KDM4E (0.53) HTTHSD17B10CYP1A2POLBALDH1A1
SCHEMBL6133255 0.85 HTT (0.47) HTTHSD17B10CYP1A2PTGS2POLB
SCHEMBL6828616 0.83 USP2 (0.43) HTTHSD17B10CYP1A2SMN1; SMN2ALDH1A1
SCHEMBL6133924 0.82 PTGS2 (0.44) HTTHSD17B10CYP1A2PTGS2SMN1; SMN2
SCHEMBL6133540 0.81 KMT2A (0.51) HTTHSD17B10CYP1A2POLBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof ASTELLAS PHARMA INC. (JP) 2005-01-06 US disclosed
EP-1441732-A2 THIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-08-04 EP disclosed
WO-2003039451-A2 THIAZOLE PYRIDAZINONES AS ADENOSINE ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-05-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050004134-A1 Thiazole derivative and pharmaceutical use thereof MC2R, CYP2C9, OXTR HTT 477/4885HSD17B10 391/4885CYP1A2 114/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.